KLF9 and hepatocellular carcinoma: For example, miR-141 could promote prostate cancer cell proliferation through inhibiting KLF9 expression while it can also inhibit vascular smooth muscle cell proliferation through targeting PAPP-A or ZEB2 to suppress HCC progression [29-31].